Key result
Elevated serum heparanase identifies CTEPH with ~0.99 diagnostic accuracy versus healthy controls.
Why the study?
Determining novel biomarkers for the early identification of chronic thromboembolic pulmonary hypertension (CTEPH) could improve patient outcomes.
Does serum heparanase (HPSE) identified via proteomic profiling accurately discriminate patients with chronic thromboembolic pulmonary hypertension (CTEPH) from healthy controls and correlate with right ventricular dysfunction?
Case-Control (n=150)
No
Does serum heparanase (HPSE) identified via proteomic profiling accurately discriminate patients with chronic thromboembolic pulmonary hypertension (CTEPH) from healthy controls and correlate with right ventricular dysfunction?
Answers are grounded in this paper and cite their sources.
Serum heparanase (HPSE) demonstrates high diagnostic accuracy (AUC 0.948-0.988) for non-invasively identifying CTEPH, correlates with impaired RV-PA coupling (TAPSE/sPAP <=0.31 mm/mmHg), and decreases significantly following balloon pulmonary angioplasty.
Determining novel biomarkers for early identification of chronic thromboembolic pulmonary hypertension (CTEPH) could improve patient outcomes. We used the isobaric tag for relative and absolute quantitation approach to compare the serum protein profiles between CTEPH patients and the controls. Bioinformatics analyses and ELISA were also performed. We identified three proteins including heparanase (HPSE), gelsolin (GSN), and secreted protein acidic and rich in cysteine (SPARC) had significant changes in CTEPH. The receiver operating characteristic curve analysis showed that the areas under the curve of HPSE in CTEPH diagnosis were 0.988. Furthermore, HPSE was correlated with multiple parameters of right ventricular function. HPSE concentrations were significantly higher in patients with a low TAPSE/sPAP ratio (≤0.31 mm/mmHg) (65.4 [60.5,68.0] vs. 59.9 [35.9,63.2] ng/mL, p < 0.05). The CTEPH patients treated by balloon pulmonary angioplasty had significantly lower HPSE levels. The study demonstrates that HPSE may be a promising biomarker for noninvasive detection of CTEPH.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2024) conducted a case-control in Chronic thromboembolic pulmonary hypertension (CTEPH) (n=150). Serum heparanase (HPSE), gelsolin (GSN), and SPARC biomarker profiling via iTRAQ proteomics and ELISA vs. Age- and sex-matched healthy controls was evaluated on Serum heparanase (HPSE) concentration (ng/mL) and diagnostic performance (ROC AUC) for distinguishing CTEPH from healthy controls in Validation Cohort 1 (AUC 0.988, p=<0.0001). Serum heparanase (HPSE) levels were elevated in CTEPH patients compared with healthy controls, yielding an AUC of 0.988 for CTEPH diagnosis.
Synapse has enriched 10 related papers. Consider them for comparative context: